Immuneering Corp Cl A IMRX

$4.07 +0.04 (0.99%)

Valuation

Market cap
263,317,000
Revenue TTM
$0
Net income TTM
$-56,020,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
588,900
Avg volume
657,038
Day's range
$4.02 – $4.14
Shares out
64,697,000
Stochastic %K
9%
Beta
0.46
Analysts
Strong Sell
Price target
$17.50

Price

Company profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical tri...

Show more

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 500 8080
Website
https://immuneering.com
Address
245 Main Street, Second Floor, Cambridge, United States

Latest news

Stocktwits

Rosalie1224 Oct 4, 1:53 AM
$IMRX $182.7M cash and securities with runway projected into 2029.//
0 replies
MikeBob15 Oct 3, 11:58 PM
$VSTM If you like this check out $CHRS in Dollar Land, with promise. Also $IMRX got sucked out, but that usually means it is something good. The new CEO sold Terns pharma for 8 billion plus to go to a company with 250 million mkt cap which he could have probably bought with his chump change. Had $VSTM but got sucked out as well... GLTA. Gotta love the BIO addiction....
1 replies
Captenotwo Oct 2, 4:08 PM
$IMRX Bought another 1,000 I think I’m at about 14,000 shares. As my Italian friend used to say “What are you gonna do?!?” Spoken with thick accent of course. Cap
1 replies
Eruption Oct 2, 3:26 PM
$IMRX And the fuckery continues.
0 replies
prevclose Oct 2, 10:46 AM
$IMRX I own Jan 27 $5 calls. Hoping something will happen by then.
0 replies
jhalimath61 Oct 2, 12:33 AM
$IMRX this used to be volatile, now it only slowly bleeds wtf
0 replies
Eruption Oct 1, 8:18 PM
$IMRX 52 week low, here we come. Wonderful.
0 replies
Eruption Oct 1, 7:47 PM
$IMRX what mfers doing this shit every day. Go f yourselves. Seriously.
1 replies